Impact of Medicare Part D Drug Manufacturer Rebates at the Point-of-Sale
November 18, 2020
A new report by Milliman shows that over the 10-year period 2022-2031, if all manufacturer rebates were reflected at the...
The pandemic is having a devastating impact on America’s seniors. The Medicare Part D prescription drug program provides our nation’s seniors with affordable drug coverage, which is more important now than ever. However, the Administration would threaten to destabilize the Medicare Part D program by dramatically increasing premiums for the vast majority of Part D enrollees.
The White House should abandon the Executive Order on rebates that would gut tools used for negotiating lower drug costs.
In collaboration with North Start Opinion Research, PCMA conducted an online on December 17-20, 2020 with 800 respondents. All respondents are age 65 or older, registered voters, and enrolled in Medicare Part D.
See Results from the Employer Rebate SurveyAll 10 surveyed state plan sponsors reported that prescription drug rebates are passed back to the plans and are used to lower enrollee premiums. Without exception, prescription drug rebates are used by plan sponsors to REDUCE COSTS AND ENHANCE BENEFITS for enrollees.
See Results from the Employer Rebate SurveyA new report by Milliman shows that over the 10-year period 2022-2031, if all manufacturer rebates were reflected at the point-of-sale in Medicare Part D, total beneficiary premiums could increase by an estimated $28.7 billion (16%) and total Federal government spending could increase by an estimated $59.5 billion.
Read Report on Point-of-Sale Rebates“The president is deeply committed to protecting America’s seniors,” Azar said. “He does not want any risk that any action could cause seniors’ premiums to increase.”
– Alex Azar, Health and Human Services Secretary
(Politico)
“Simply trying to eliminate rebating without any other steps threatens to drive up drug prices overall…Rebates are a key mechanism that insurers use to try to reduce net drug prices.”
– Aaron Kesselheim, Associate Professor of Medicine, Harvard Medical School
(Read more quotes: Coalition for Affordable Prescription Drugs)
“I have never seen a regulatory impact statement on a proposed rule state so clearly that the impacts are impossible to know and that the best analyses suggest some very negative results such as higher premiums in Medicare Part D and overall higher drug costs.”
– Ian Spatz, Senior Advisor, Manatt Health
(Read more quotes: Coalition for Affordable Prescription Drugs)
‘‘The concern remains that this move fails to address the root cause of high prescription drug costs which starts with list prices set by drug manufacturers…The proposed rule risks destabilizing Part D premiums for seniors.”
– Allyson Y. Schwartz, CEO, Better Medicare Alliance
(Read more quotes: Coalition for Affordable Prescription Drugs)
Impact of Medicare Part D Drug Manufacturer Rebates at the Point-of-Sale
November 18, 2020
A new report by Milliman shows that over the 10-year period 2022-2031, if all manufacturer rebates were reflected at the...
Negative Economic Impact of Restricting Drug Rebates in Medicare Part: Matrix Global Advisors
September 02, 2020
“Negative Economic Impact of Restricting Rebates in Medicare Part D,” by Alex Brill of Matrix Global Advisors (MGA), examines recent...
Americans’ Opinions on the Elimination of Rebates in Medicare Part D
August 13, 2020
A majority of seniors say they are satisfied with their prescription drug coverage… Read More...
Survey Says: Americans 65+ Disapprove of President Trump’s Rebate Rule
August 10, 2020
In a recent survey conducted by Morning Consult on behalf of the Coalition for Medicare Choices, we asked voters 65+...
National Survey of Seniors Regarding the Medicare Part D Prescription Drug Benefit
March 18, 2019
See topline points from the “National Survey of Seniors Regarding the Medicare Part D Prescription Drug Benefit”...
October 12, 2020
As the world responds to the COVID-19 pandemic, the sheer amount of investment going into efforts to come up with...
Forbes: PBM Rebates Do Not Cause Higher Medicare Part D Drug Prices
October 12, 2020
The federal government spends a lot of money on prescription drugs. Medicare Part D, the program to help seniors pay...
September 10, 2020
The Trump administration’s recent release of a series of drug pricing executive orders is leading to more questions than answers....
PCMA Statement on the ‘Counteroffer’ by Drug Companies to the Administration
August 26, 2020
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the reported...
Visante: Artificial Manufacturer Barriers to Competition Lead to High Insulin Prices
August 17, 2020
(Washington, D.C.) — A highly consolidated insulin market limits competition and allows dramatic price increases on new and existing brand-name products, according to...
August 03, 2020
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) is announcing the launch of the next series of ads as...